Company Overview and News

 
Urstadt Biddle Properties (UBA) Surpasses Q3 FFO and Revenue Estimates

2018-09-07 zacks
Urstadt Biddle Properties (UBA - Free Report) came out with quarterly funds from operations (FFO) of $0.35 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to FFO of $0.37 per share a year ago. These figures are adjusted for non-recurring items.
UBA UBP

 
UBP / Urstadt Biddle Properties, Inc. THIRD QUARTER EARNINGS 8K 2018 (Current Report)

2018-09-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UBP

 
UBP / Urstadt Biddle Properties, Inc. FORM 10Q 3Q 2018 (Quarterly Report)

2018-09-07 sec.gov
  United States Securities And Exchange Commission Washington, DC 20549
UBP

5
Urstadt Biddle Properties: Hold For The Coming 2019 Catalyst

2018-08-23 seekingalpha
As a fairly obscure regional shopping center Real Estate Investment Trust (REIT), Urstadt Biddle Properties is little known to most investors.
UBA UBP ODP DTK BBBY

 
UBP / Urstadt Biddle Properties, Inc. RIGHTS AGREEMENT 08132018 (Current Report)

2018-08-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UBP

1
Urstadt Biddle Properties Sees Hammer Chart Pattern: Time to Buy?

2018-08-08 zacks
Urstadt Biddle Properties Inc. (UBA - Free Report) has been struggling lately, but the selling pressure may be coming to an end soon. That is because UBA recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
UBA UBP KRO CIVI SBOW

 
Is Urstadt Biddle Properties (UBA) a Great Dividend Play?

2018-07-26 zacks
All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
UBA UBP IBCP IBTX INDB

 
A Health Care REIT That Willy Wonka Would Love

2018-07-23 seekingalpha
While some pundits believe that skilled nursing rents will continue to decline, the bulls (like me) argue that the supply and demand fundamentals will drive returns.
UBA 3290 HCP O NHLG OPRF NHC UBP UHT ESS OHI NHI NNN

 
Has Urstadt Biddle Properties (UBA) Outpaced Other Finance Stocks This Year?

2018-07-12 zacks
For those looking to find strong Finance stocks, it is prudent to search for companies in the group that are outperforming their peers. Urstadt Biddle Properties (UBA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of UBA and the rest of the Finance group's stocks.
UBA UBP

 
UBA or BFS: Which Is the Better Value Stock Right Now?

2018-07-12 zacks
Investors looking for stocks in the REIT and Equity Trust - Retail sector might want to consider either Urstadt Biddle Properties (UBA - Free Report) or Saul Centers (BFS - Free Report) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
UBA UBP BFS

3
Moving Average Crossover Alert: Urstadt Biddle Properties (UBA)

2018-06-27 zacks
Urstadt Biddle Properties Inc. (UBA - Free Report) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for UBA broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend.
UBA UBP DY ICHR

4
Hey Diddle Diddle, I'm Upgrading Urstadt Biddle

2018-06-11 seekingalpha
Back in March I wrote an article on Urstadt Biddle (UBA) titled, Urstadt Biddle Could Become Another 'Cinderella Story, in which I explained that after “reviewing the recent earnings results, UBA has earned a ticket to the Sweet Sixteen and I have upgraded shares to a STRONG BUY.”
UBA WFM UBP FRT

1
UBP / Urstadt Biddle Properties, Inc. FORM 10Q 2Q 2018 (Quarterly Report)

2018-06-08 sec.gov
  United States Securities And Exchange Commission Washington, DC 20549
UBP

1
UBP / Urstadt Biddle Properties, Inc. SECOND QUARTER EARNINGS 8K 2018 (Current Report)

2018-06-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UBP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...